Titre:
  • Randomised trial of trastuzumab deruxtecan and biology-driven selection of neoadjuvant treatment for HER2-positive breast cancer: a study protocol of ARIADNE.
Auteur:Matikas, Alexios; Naume, Bjorn; Wildiers, Hans; Sonke, Gabe GS; Dieci, Maria Vittoria; Karakatsanis, Andreas; Andersson, Anne; Barnekow, Elin; Kessler, Luisa Edman; Einbeigi, Zakaria; Killander, Fredrika; Linderholm, Barbro B.K.; Schiza, Aglaia; Valachis, Antonis; Nearchou, Andreas; Engebraaten, Olav; Porojnicu, Alina; Soland, Mari Hiorth; Mannsåker, Bård; Raj, Sunil Xavier; Blix, Egil Støre; Nordstrand, Cecilie Soma; Lambertini, Matteo; Vernieri, Claudio; Punie, Kevin; Sotiriou, Christos; Bergh, Jonas; Villacampa, Guillermo; Zouzos, Athanasios; Hellström, Mats; Hartman, Johan; Foukakis, Theodoros
Informations sur la publication:BMJ open, 15, 8, page (e102626)
Statut de publication:Publié, 2025-08
Sujet CREF:Sciences bio-médicales et agricoles
Mots-clés:Breast tumours
Clinical trials
Drug Therapy
MeSH keywords:Female
Humans
Antibodies, Monoclonal, Humanized -- therapeutic use -- administration & dosage
Antineoplastic Agents, Immunological -- therapeutic use
Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
Breast Neoplasms -- drug therapy -- metabolism
Carboplatin -- administration & dosage -- therapeutic use
Clinical Trials, Phase II as Topic
Docetaxel -- administration & dosage
Immunoconjugates -- therapeutic use -- administration & dosage
Neoadjuvant Therapy -- methods
Paclitaxel -- administration & dosage -- therapeutic use
Randomized Controlled Trials as Topic
Receptor, ErbB-2 -- metabolism
Trastuzumab -- therapeutic use -- administration & dosage
Multicenter Studies as Topic
Camptothecin -- analogs & derivatives
Langue:Anglais
Identificateurs:urn:issn:2044-6055
info:doi/10.1136/bmjopen-2025-102626
info:pii/bmjopen-2025-102626
info:pmid/40866060
PMC12410627